AML1, the potent transcription factor in hematopoiesis, is antagonized by AML1-ETO in t(8;21) leukemia. Our previous study showed that the differentiation and apoptosis of Kasumi-1 induced by sodium phenylbutyrate (PB), were accompanied by significant upregulation of PIG7 and AML1b (one of the AML1 isoforms). Here, we further investigated the relationship between AML1b and PIG7, also the effects of PIG7 on leukemia cells. The results demonstrated that exogenous AML1b could upregulate PIG7 expression in HEK-293 and CV-1 cells in sequence-specific and dosage-dependent manners, and this effect was antagonized by AML1-ETO. The specific AML1-binding site required for p53-induced gene 7 (PIG7) transactivation was located between nucleotides À1511 and À1503 in the PIG7 promoter. Overexpression of PIG7 could induce the apoptosis and differentiation of Kasumi-1 and SKNO-1 cells, but showed less effect on NB4 cells directly. Moreover, ectopic expression of PIG7 could sensitize these cell lines to PB or all-trans retinoic acid, respectively, which could then be abrogated by downregulation of PIG7 expression. Furthermore, the primary acute myeloid leukemia cells showed similar response to the ectopic expression of PIG7. In conclusion, PIG7 could be transactivated by AML1, which subsequently induces differentiation and apoptosis of leukemia cells, especially those with AML1-ETO fusion gene.
Introduction
AML1 occurs in the early stage of embryo formation and has an important role by regulating a variety of hematopoiesisrelated genes.
1,2 AML1b, the predominant isoform of AML1 in normal hematopoietic stem cells, encodes an important transcription factor and promotes hematopoietic stem cell development and differentiation.
3 AML1b also has a DNA binding domain, known as the Runt homology domain, and a transactivation domain. 4 In t(8;21) acute myeloid leukemia (AML), the chromosomal translocations results in the formation of AML1-ETO fusion protein retaining Runt homology domain, but lacks the transactivation domain. 5, 6 AML1-ETO recruits a complex containing nuclear receptor co-repressor/mSin3/ histone deacetylase (HDAC), facilitated a closed chromatin structure and mediates transcriptional repression of AML1b target genes. [7] [8] [9] The competitive inhibition of AML1-ETO to AML1b is an important mechanism in leukemogenesis. Thus, inhibiting HDAC function and sequential restraining of AML1-ETO are suggested to be practicable in leukemia therapy.
The Kasumi-1 cell line used as a model system of AML is notoriously characteristic of fusion protein AML1-ETO. 10 As demonstrated by our previous study, sodium phenylbutyrate (PB), one of the HDAC inhibitors, could induce Kasumi-1 cells to undergo differentiation and apoptosis. 11 To analyze the changes of gene expression profile related to differentiation and apoptosis, PB-treated Kasumi-1 cells were applied to oligonucleotide array (HG-U95 Av2, Affymetrix, Santa Clara, CA, USA) analysis. The levels of p53-induced gene 7 (PIG7) and AML1b were increased by 2 7.8 -and 2 3.3 -folds, respectively. 12 This result suggested that AML1b and PIG7 may have contributed to the differentiation and apoptosis of leukemia cells induced by PB. PIG7 performs a similar function as nuclear factor-kB to regulate tumor necrosis factor-a transcription. 13 It had been reported that the element required for PIG7 transcriptional activity induced by p53 is mainly located from nucleotides (nt) À990 to À500 in the promoter region of the PIG7 gene. 14 Although there were seven putative AML1-binding sites within 3000 nt upstream of PIG7 transcription start site. This also implied that the transcription of PIG7 may be regulated by AML1.
In this study, we explored the role of AML1b/AML1-ETO in the regulation of PIG7 gene transcription. In addition, whether PIG7 was associated with differentiation or apoptosis of leukemia cells was further investigated in leukemia cell lines (Kasumi-1, SKNO-1 and NB4) and primary AML cells by lentivirus transduction of PIG7 and its antisense RNA sequence. The results revealed that PIG7 was transactivated by AML1b through the specific AML1-binding site located between nt À1511 and À1503 in the PIG7 gene promoter; moreover, it could promote apoptosis and differentiation of leukemia cells, especially those with AML1-ETO fusion gene.
Materials and methods

Construction of reporter gene vectors and lentiviral vectors
A series of human PIG7 promoter/enhancer DNA fragments containing putative AML1-binding sequences were generated from human genomic DNA by PCR, containing 3, 1, 3 putative AML1 protein-binding sites. The sequences of the primers were devised as follows: (1) 5 0 -CGCACGCGTGGACAATGTTG GACAGAG-3 0 and 5 0 -GGAAGATCTCTGCCATTCCTCCATTC
0 . These amplified fragments of 774, 860 and 1002 bp were subcloned into the pGL3-promoter/basic vector and named as S774P, S860P and S1002B, respectively. A mutant DNA fragment of the 860 bp was generated following three rounds of PCR with the primer pairs: (4) 5 0 -CGCACGCGTCACCACTCCACCGCTTTA-3 0 and 5
0 . It was then inserted into the pGL3-promoter vector and named as Mu860P.
The fragments containing PIG7 open reading frame and two antisense oligonucleotides were amplified by PCR from pMD18T-PIG7 plasmid. 12 The sequences of the primers were shown in the 'Supplementary Materials and Methods'. The fragments were subcloned into pCDH1-MCS1-EF1-copGFP (System Biosciences, Mountain View, CA, USA) and named as pCDH-PIG7, pCDH-anti-PIG7-1 and pCDH-anti-PIG7-2, respectively. The empty vector pCDH1-MCS1-EF1-copGFP was used as a parallel control vector and named as pCDH in brief in this study.
Cells and culture condition
African green monkey kidney cell line CV-1 and human embryonic kidney cell line HEK-293 were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum. Kasumi-1, SKNO-1 and NB4 cells were routinely maintained in RPMI-1640 medium supplemented with 15%, 15% and 10% fetal bovine serum, respectively. SKNO-1 was also supplemented with 10 ng/ml recombinant human granulocyte-macrophage colony-stimulating factor.
Bone marrow samples were obtained from nine primary AML patients (four AML with t(8;21), five AML with t(15;17)) and six healthy donors as control enrolled in the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. All patients and donors gave informed consent. The diagnosis and classification of the leukemia were based on 2008 World Health Organization's criteria. Bone marrow mononuclear cells were cultured in Iscove's modified Dulbecco's media supplemented with 15% fetal bovine serum for subsequent lentiviral infection.
Quantitative real-time RT-PCR
After transfected with 80 ng of pCMV5-AML1b, pCMV5-AML1-ETO alone or in combination and pCMV5 control by calcium phosphate-mediated precipitation for 48 h, CV-1 and HEK-293 were collected and the quantitative real-time RT-PCR (qRT-PCR) was performed according to our previous study. 12 The relative expression values were normalized to glyceraldehyde 3-phosphate dehydrogenase for cell lines or the median PIG7 expression of six healthy donors for primary leukemia cells.
Western blot analysis
The expression of AML1b, AML1-ETO and PIG7 were confirmed by western blot after they were transfected with 1 mg of pCMV5-AML1b, pCMV5-AML1-ETO alone or in combination and pCMV5 control. The following antibodies were used: anti-PIG7 monoclonal antibody (BD Biosciences, San Diego, CA, USA), anti-AML1/RUNX1 polyclonal antibody (Abcam, Cambridge, UK) and anti-ETO polyclonal antibody (Merck KGaA, Darmstadt, Germany). Anti-actin monoclonal antibody (Sigma, Taufkirchen, Germany) was used as internal control. The immunoreactive proteins were visualized using the SuperSignal chemiluminescent detection system (Pierce, Rockford, IL, USA) in a similar exposure time.
Transient luciferase assay
After transfected by calcium phosphate-mediated precipitation for 48 h, CV-1 and HEK-293 were collected for assays of b-galactosidase and luciferase activity according to the DualLuciferase Reporter 1000 Assay System Technical Manual (Promega, Madison, WI, USA) by luminometer (Lumat LB 9507, Berthold Technologies GmbH & Co. KG, Baden-Wü rttemberg, Germany). The following combinations of plasmids were used: 750 ng S774P, S860P, S1002B or Mu860P reporter plasmids with different dosage of pCMV5-AML1b or pCMV5-AML1-ETO and with 750 ng b-galactosidase plasmids.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation analysis was performed with sonication method (Supplementary Materials and Methods). The purified chromatin from NB4 cells was immunoprecipitated with anti-AML1b antibody (Abcam), and immunoglobulin G isotype was used as control. The eluted DNA was purified, and used as PCR template to amplify the promoter sequences between nt À1614 and À1474 containing putative AML1b-binding site at nt À1511 to À1503 of PIG7 with the following primers: 5 0 -TTAGGACCTCGGGTAAA-3 0 (forward) and 5 0 -CAG GAGATGGGCAGAA-3 0 (reverse).
Lentivirus production and transduction
The lentiviral vector constructs were co-transfected into 293T cells with pPACK packaging plasmid mix (System Biosciences) using calcium phosphate precipitation method. Infectious lentiviruses were collected at 48 and 72 h after transfection and concentrated to 100-fold by ultracentrifugation. The leukemia cells were transduced with prepared lentivirus. Transgene expression was detected by semi-quantitative RT-PCR 15 and western blot.
Apoptosis assessment by Annexin V staining
Kasumi-1, SKNO-1 and NB4 cells were infected with lentivirus, and then parts of them were incubated with PB of 1, 2 and 3 mM, or all-trans retinoic acid (ATRA) of 1, 2 and 3 mM, respectively. The cells were collected at different time and analyzed for apoptosis by Annexin V-PE/7-AAD kit (BD Biosciences) according to the manufacturer's instructions. The primary bone marrow mononuclear cells were also transduced with lentivirus and apoptotic assay was performed. All the samples were analyzed by FACScalibur flow cytometer (Becton Dickinson Immunocytometry Systems; San Jose, CA, USA). The apoptotic cells in the green fluorescent protein (GFP)-positive cell portions were calculated.
Apoptosis assessment by DNA fragmentation analysis
Leukemia cells treated with drug alone or drug/virus combination were performed by DNA fragmentation analysis as that described in Supplementary Materials and Methods.
Fluorescence-activated cell sorting and morphological analysis of GFP-positive cells
Kasumi-1 and NB4 cells treated with drug alone or drug/virus combination were sorted for GFP-positive cell populations on flow cytometer (BD FACS Aria II System; San Jose, CA, USA). Then the cytospins of GFP-positive cells were prepared and stained with Wright and Giemsa stain for identification of cell morphology. The images were captured by the Nikon Eclipse 50i microscope (Nikon Inc., Melville, NY, USA).
Flow cytometry analysis
For cell surface markers analysis, the monoclonal antibody against CD11b and CD16 (Becton Dickinson) was used and assayed by FACScalibur flow cytometer. The GFP-positive cell proportions were analyzed.
Statistical analysis
Three repetitions were performed for each experiment. The significance of differences between two groups was determined using paired t-test. All analyses were carried out using the SPSS software package (SPSS, Chicago, IL, USA). Po0.05 was deemed statistically significant.
Results
AML1b upregulated the expression of PIG7
Having demonstrated by our previous study that the expression of PIG7 and AML1b was increased in PB-induced Kasumi-1 cells, we investigated whether PIG7 was regulated by AML1b. After transfected with pCMV5-AML1b and pCMV5-AML1-ETO (80 ng/5 Â 10 5 cells), the endogenous mRNA levels of PIG7 in CV-1 and HEK-293 cells were analyzed by qRT-PCR. The results showed that the PIG7 mRNA of the pCMV5-AML1b group was upregulated to 310±32% in CV-1 cells, and 223±19% in HEK-293 cells compared with that of pCMV5 control group (Po0.05). However, no difference was observed between the pCMV5-AML1-ETO group and the empty vector group (P 40.05) (Figure 1a ).
To further study whether there is competitive inhibition effect of AML1-ETO on AML1b in activating PIG7 transcription, pCMV5-AML1b and pCMV5-AML1-ETO were co-transfected into CV-1 and HEK-293 cells at the same dose (80 ng/5 Â 10 5 cells). The qRT-PCR showed that the PIG7 mRNA level of the co-transfected group was reduced to (47.9±4.4%) in CV-1 cell and (48.1 ± 14.1%) in HEK-293 cells (Po0.05) compared with the pCMV5-AML1b group. It indicated that there is competitive inhibition effect of AML1-ETO on AML1b in activating PIG7 transcription. Western blot analysis was performed in HEK-293 cells to confirm the qRT-PCR result. As shown in Figure 1b , the protein level of PIG7 was upregulated by 1 mg of pCMV5-AML1b, but this effect was abrogated by addition of same dose of pCMV5-AML1-ETO. It seemed that PIG7 is downregulated with the overexpression of AML1-ETO. Furthermore, PIG 7 upregulation was accompanied with knockdown of AML1-ETO in Kasumi-1 cells by PB treatment in the qRT-PCR analysis (Supplementary Figure 1) .
AML1b could transactivate the PIG7 promoter
As shown in the above study, the endogenous expression of PIG7 could be upregulated by AML1b, and on the other hand, there are putative AML1-binding sites within the enhancer/ promoter region of PIG7 gene; there might be possible links between transactivation of PIG7 gene and AML1 binding to its promoter. To this end, we generated a serial of PIG7 luciferase reporter gene constructs to analyze the transactive effect of AML1b and AML1-ETO on PIG7. Of them, S1002B contained three putative AML1 protein-binding sites (nt À962 to À955 TTGGTGGTC, À291 to À283 CTCCGGTT and À82 to À56 TTTTGGTT) was fused to luciferase reporter vector pGL3-basic; whereas S860P containing one putative AML1-binding site (nt À1511 to À1503 TTTGTGGAT) and S774P containing three putative AML1-binding sites (nt À2764 to À2756 TCTGTGGTT, À2663 to À2655 TTTGTGTTT, À2606 to À2598 GATGTGGTA) to pGL3-promoter vector (Figure 2a) .
Each of these luciferase reporter gene constructs was co-transfected with pCMV5-AML1b or pCMV5-AML1-ETO into CV-1 cells, respectively. The luciferase activity was analyzed by luminometer at 48 h after transfection. As shown in Figure 2a , only the luciferase activity of S860P was activated by AML1b. It indicated that the element required for AML1b transactivation activity was mainly located between nt À1945 and À1086 upstream of the PIG7 transcription start site. Moreover, AML1b transactivated the PIG7 promoter in a dosedependent manner, and a 3.5-fold increase in S860P luciferase activity was observed in pCMV5-AML1b group at a dose of 80 ng. There was no obvious change in the luciferase activity of pCMV5-AML1-ETO group at different doses ( Figure 2b ). The transactivation of the PIG7 promoter mediated by AML1b was abrogated by AML1-ETO in a dose-dependent manner (Figure 2c ). The luciferase activity was reduced to 39.2 ± 3.2% after co-transfected with pCMV5-AML1-ETO at the dose of 80 ng. These results showed that AML1-ETO could antagonize the transactivation of AML1b to the PIG7 promoter. 
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On the basis of the above results, we presumed that the TTTGTGGAT sequence in S860P is likely the binding site for AML1. To demonstrate this 'site-specificity', Mu860P with mutated TTTGTGGAT to TTCGAGTAT was co-transfected with pCMV5-AML1b or pCMV5-AML1-ETO into CV-1 cells (Figure 2a) . The transactivation of PIG7 promoter by AML1b was completely abolished when AML1-binding site was mutated (Figure 2d) , and there was no difference in the luciferase activity after AML1-ETO overexpressed, whether in S860P or in Mu860P group (Figure 2e) . Taken together, the findings suggested that AML1b protein might bind to PIG7 promoter at nt À1511 to À1503, transactivate the PIG7 promoter and upregulate its expression.
To further confirm the specific binding of AML1b to PIG7 promoter at nt À1511 to À1503, chromatin immunoprecipitation assays were performed using AML1b-expressing NB4 cells.
As shown in Figure 2f , the fragment between nt À1614 and À1474 containing the putative AML1b-binding site at nt À1511 to À1503 of PIG7 was successfully amplified, both from the input DNA and the chromatin immunoprecipitated by antiAML1b antibody, whereas no amplified product was obtained in the immunoglobulin G isotype control group. The chromatin immunoprecipitation data demonstrated the in vivo-specific binding of AML1b to enhancer domains in the cis-regulatory region nt À1511 to À1503 of the PIG7 promoter.
Overexpression of PIG7-induced apoptosis of leukemia cell lines
It was observed in our previous study that apoptosis of Kasumi-1 cells, induced by PB treatment, was accompanied by upregulation of PIG7 expression. In order to explore whether PIG7 gene is a proapoptotic factor for leukemia cells, Kasumi-1, SKNO-1 and NB4 cells were infected with PIG7 lentivirus. Ectopic expression of PIG7 was confirmed by RT-PCR (Figure 3a ) and western blot (Figure 3b ). On the other hand, the upregulated endogenous PIG7 expression in these cell lines induced by PB or ATRA could be partially abrogated by pCDH-anti-PIG7-1/2.
We then examined whether the ectopic expression of PIG7 after lentivirus infection could induce apoptosis with or without PB/ATRA treatment. The results revealed that apoptosis in Kasumi-1 and SKNO-1 cells, but not in NB4 cells, could be significantly induced by ectopically expressed PIG7 compared with that in control group (Po0.05), whereas the apoptosis induced by the ectopically expressed PIG7 could be enhanced further by PB or ATRA treatment (Po0.05; Figures 4a, c and e) . To further confirm the apoptotic effects induced by PIG7, the cells were infected with lentivrus-expressing antisense RNA of PIG7, and then exposed to PB and ATRA, respectively. As a result, the apoptosis of Kasumi-1, SKNO-1 and NB4 induced by PB or ATRA was abolished partly by the pre-treatment of above cells with antisense RNA of PIG7. Apoptosis of the cells mediated by PIG7 together with PB or ATRA was also demonstrated by DNA ladder analysis (Figures 4g-i) . Moreover, GFP-positive Kasumi-1 and NB4 cells in pCDH-PIG7 þ PB/ ATRA groups showed distinct morphological changes of apoptosis (Figure 4j ). The cells showed indented nuclei, reduced ratio of nucleus to cytoplasm, or condensed nuclei with apoptotic body appearing concomitantly compared with those in pCDH control groups; whereas in other groups, the morphological changes were not so obvious. These results were coincident with those in the apoptosis assays.
We also tried another HDAC inhibitor, valproic acid, to perform the apoptosis assay. The results also showed that the early apoptosis of SKNO-1 could be induced by ectopic expression of PIG7 and enhanced by treatment with valproic acid (Supplementary Figure 2a) .
Overexpression of PIG7-induced differentiation of leukemia cell lines
To examine whether upregulation of PIG7 gene expression could induce differentiation of leukemia cells as well, the expression levels of cell surface markers CD11b and CD16 were analyzed. The proportion of CD11b þ and CD16 þ Kasumi-1 and SKNO-1 cells increased notably after infection with pCDH-PIG7 (Po0.05) (Figures 5a, c, e and g ), whereas no parallel changes were found in NB4 cells (P40.05) (Figures 5i and k) . Upregulation of PIG7 could also render the cells susceptible to the induction of differentiation by PB or ATRA, the expression levels of CD11b and CD16 in the cell lines increased considerably compared with those in pCDH þ PB/ATRA groups (Po0.05). In addition, the expression of CD11b and CD16 induced by PB or ATRA were inhibited significantly in pCDHanti-PIG7-1 þ PB/ATRA group, compared with that of pCDH þ PB/ATRA groups (Po0.05) (Figures 5b, d, f and h ). This effect in SKNO-1 cells was not so obvious (P40.05). When treated with 1 mM valproic acid, the expression of CD11b and CD16 also increased notably compared with the untreated group (Supplementary Figures 2b and c) .
Nitroblue tetrazolium reduction assay showed that there was no apparent difference in the pCDH, pCDH-PIG7 and pCDHanti-PIG7-1 group, which indicated PIG7 could not sufficiently induce the terminal differentiation of Kasumi-1, NB-4 and SKON-1 cells (Supplementary Figure 3) .
Effect of ectopic PIG7 expression on primary AML cells with t(8;21)
We further investigated whether upregulation of PIG7 expression in primary leukemia cells could lead to the similar effects on differentiation and apoptosis. To normalize apoptosis and differentiation between different patients, the relative apoptosis and differentiation rates in pCDH-PIG7 group versus those in pCDH group were used. In t(8;21) AMLs, the relative apoptosis Figure 3 Expression of PIG7 mediated by lentivirus infection and PB/ATRA treatment. In Kasumi-1, NB4 and SKNO-1 cells, high levels of PIG7 product could be detected in pCDH-PIG7 group and pCDH þ PB/ATRA group by RT-PCR (a) and western blot (b) after infected with lentivirus for 48 h. The upregulated PIG7 expressions were abrogated significantly by pCDH-anti-PIG7-1/2, whereas the endogenous PIG7 expression was higher in SKNO-1 cells. The effects of 1 mM PB were not obvious.
PIG7 on differentiation and apoptosis of leukemia cells J Liu et al Figure 4 Changes of apoptosis of leukemia cells after lentivirus infection and PB/ATRA treatment. (a-f) Annexin V staining assay indicated that increased rate of apoptosis in Kasumi-1, SKNO-1 cells infected with pCDH-PIG7 lentivirus alone, whereas little changes in NB4 cells were observed. When combined with PB/ATRA at different concentration, the apoptotic rate of these cell lines also increased notably compared with pCDH control þ PB/ATRA groups (Po0.05). Treatment with both pCDH-anti-PIG7-1 and PB/ATRA could reduce cells apoptosis compared with pCDH control þ PB/ATRA groups. Typically pronounced DNA ladder was observed in the pCDH þ PB/ATRA group, especially in the pCDH-PIG7 þ PB/ATRA group. No DNA ladder was observed in pCDH parallel control group, pCDH-PIG7 group and pCDH-anti-PIG7-1 group (g-i). Kasumi-1, SKNO-1 and NB4 were detected after lentivirus infection for 60, 72 and 36 h, respectively. (j) The morphological changes of kasumi-1 and NB4 cells after lentivirus infection and PB/ATRA treatment. After overexpression of PIG7 and treated with PB/ATRA, GFP-positive Kasumi-1 and NB4 cells behaved distinct morphological changes of apoptosis. In pCDH-PIG7 þ PB/ATRA groups, cells showed indented nuclei, reduced ratio of nucleus to cytoplasm, or condensed nuclei with apoptotic body appearing concomitantly (Wright and Giemsa stain, original magnification Â 1000). 05) (a, c, e, g ). The expression levels of CD11b and CD16 decreased significantly in pCDH-anti-PIG7-1 þ PB group compared with pCDH þ PB groups in Kasumi-1 cells (Po0.05) (b, d), while not in SKNO-1 cells (P40.05) (f, h). Treatment with pCDH-PIG7 alone could not affect differentiation status in NB4 cells (P40.05). When combined with ATRA at different concentration, CD11b and CD16 also increased remarkably compared with pCDH þ ATRA groups (Po0.05) (i, k). The expression levels of CD11b and CD16 decreased significantly in pCDH-anti-PIG7-1 þ ATRA group compared with pCDH þ ATRA groups (Po0.05) (j, l). Kasumi-1, SKNO-1 and NB4 were detected after lentivirus infection for 60, 72 and 36 h, respectively. rate ranged from 1.29-to 2.58-fold (48 h) and 1.24-to 3.63-fold (72 h) compared with that of the pCDH group, respectively, (Figure 6a ). There were also elevated ratios of CD11b þ cells and CD16 þ cells in these samples (Figures 6c and e) , whereas in t(15;17) AMLs, only two cases had elevated relative CD11b expression rate at 72 h (2.37-and 2.84-fold, respectively) ( Figure 6d ). No obvious change in apoptosis and CD16 expression were observed (Figures 6b and f) . It is hard to draw a definite conclusion at this time as the number of samples is insufficient, and more primary samples were required to confirm the effect of upregulation of PIG7 on the differentiation and apoptosis of leukemia patients.
Discussion
AML1 is a sequence-specific DNA binding protein that complexes with core-binding factor beta to activate transcription of genes related with the proliferation and differentiation of hematopoietic progenitors. AML-ETO fusion protein functions as a dominant negative repressor of AML1 target genes and leads to a block in myeloid development and leukemic transformation of the maturing hematopoietic progenitors. 3, 5, [16] [17] [18] HDAC inhibition is suggested to be effective to overcome the effects of AML1-ETO and lead to reversal of the t(8;21) leukemia, and is expected Figure 6 Relative levels of apoptosis and differentiation in AML with t(8;21) and AML with t(15;17) after lentivirus infection, and the relative expression of PIG7 mRNA of the patients. The relative levels of apoptosis obviously increased in the bone marrow mononuclear cells of AML with t(8;21) than those of AML with t(15;17) infected with pCDH-PIG7 lentivirus (a, b). There was also distinct increase of differentiated cells in two of four t(8;21) AML patients (c, e), wereas only two of the five t(15;17) AML patients showed increased CD11b expression at 72 h (d). There was no difference in CD16 expression in the AML patients with t(15;17) (f). a, c, e Are for four AMLs with t(8;21); b, d, f Are for five AMLs with t(15;17). The bone marrow mononuclear cells from the patients were subjected to PIG7 mRNA assay by qRT-PCR (g). Relative quantification was normalized to the median of the healthy donors (n ¼ 6). Error bars indicate s.d. Western blot assay showed the expression of PIG7 protein after lentivirus infection for 48 h. Actin was used as protein loading control (h).
PIG7 on differentiation and apoptosis of leukemia cells J Liu et al for clinical use in AML patients for its relatively low risk of serious toxicity. 19, 20 As one of the effective HDAC inhibitor, PB induces differentiation, inhibits proliferation of AML cell lines and primary leukemia cells in vitro. 21, 22 A Phase I study of continuous infusions of PB in patients with myelodysplastic syndrome or AML demonstrated promising preliminary evidence of clinical activity. 23, 24 It is necessary to recognize more molecular mechanism that associated with the proliferation inhibition and differentiation induction of PB.
Our previous study found that PIG7 was strikingly elevated in Kasumi-1 cells after PB treatment. Over the last decade, several lines of evidence have indicated possible roles of PIG7 abnormality in pathogenesis of some malignancies, such as downregulated in the carcinoma of urinary bladder and breast cancer and 25, 26 mutated in Paget's disease. 27 Upregulation of gene expression was also detected in methionine-induced apoptosis of melanoma cells. 26 PIG7 was silenced by homozygous deletion in primary mediastinal B-cell lymphoma and by promoter hypermethylation in germinal center lymphoma. 28 Our previous study had also revealed that there was a striking decrease of PIG7 expression in newly diagnosed and refractory/ relapsed acute leukemia patients, also in seven of nine leukemia cell lines in comparison with healthy donors and acute leukemia patients in complete remission by using qRT-PCR. 12 The methylation-specific PCR analysis showed that K562, HL60 cells with low expression of PIG7, presented excessive methylation in the promoter region (data not shown). However, there was no significant methylation found in the promoter region of Kasumi-1 cells, which also had low expression of PIG7. This prompted other possible way leading to reduced expression of PIG7. On the other hand, oligonucleotide array analysis with PB-treated Kasumi-1 cells showed upregulation of PIG7 and AML1b. 12 Kasumi-1 cells with t(8;21) chromosomal translocation have the advantages of expressing AML1-ETO fusion protein, which inhibits the transcriptional activity of AML1b. Above information suggested that low expression of PIG7 in Kasumi-1 cells might be related to the predominant expression of AML1-ETO or the decreased expression of AML1b.
We transfected AML1b into CV-1 and HEK-293 cells, which resulted in the upregulation of PIG7. Luciferase transcriptional activity analysis showed that the luciferase activity of the S860P containing nt À1511 to À1503 fragment was upregulated by co-transfected pCMV5-AML1b vector and had apparent 'doseeffect' relationship. The transactivation of PIG7 mediated by AML1b was abrogated by co-transfection with AML1-ETO in a dose-dependent manner. The specificity of the DNA sequence was also verified by using point-mutated luciferase reporter construct.
Many studies have shown that transcripts of PIG7 gene can inhibit tumor cell growth. 15, 29 That mechanism can be attributed to PIG7 in the regulation of apoptosis, but the universality needs to be considered with background of specific cells. In our previous study, we found that ectopic expression of PIG7 in K562, Raji and HL60 could not affect differentiation status, proliferation potential or apoptosis induction. Interestingly, when combined with cytotoxic drugs such as etoposide and daunorubicin, a sensitizing effect could be observed. 12 In this study, we found ectopic expression of PIG7 could directly induce apoptosis and promote differentiation in Kasumi-1 and SKNO-1 with the upregulation of CD11b and CD16 expression by flow cytometric assay. However, the changes were not obvious in NB4 cells. When combined with ATRA, a sensitizing effect could also be observed.
As we expected, downregulation of endogenous PIG7 expression by pCDH-anti-PIG7 could assuredly decrease the rate of apoptosis and differentiation significantly. We ascribed this unique phenomenon to the nature of PIG7 as an essential element in lysosome-mediated protein degradation pathway. Most probably, PIG7 adjusts the balance between apoptotic and anti-apoptotic factors, differentiation and anti-differentiation factors in protein levels. It may also be involved in renewing of intracellular targets of differentiation agents by accelerating removal of misfolding protein product or functioning as a scavenger, removing factors responsible for drug resistance in leukemia cells, hence sensitizing leukemia cells to these agents. 12 The results obtained in the primary leukemia cells showed an apparent tendency that coincided with those in leukemia cell lines. The differentiation and apoptosis were obviously increased in t(8;21) AMLs. However, the differentiation status or apoptosis induction in t(15;17) AML was not affected unanimously by PIG7 upregulation. We selected one t(15;17) AML case to execute the drug sensitivity assay. After treatment with 3 mM ATRA, the expression of CD11b, as well as apoptotic rate, all showed pronounced increasing (data not shown). Our data also showed that the upregulation of differentiation and apoptosis in one t(8;21) AML case was not as notable as that in other three cases. Moreover, there was also high expression of CD11b in three t(15;17) AML cases after transduced with pCDH-PIG7 lentivirus. Interestingly, the qRT-PCR assay showed that the patients with lower endogenous PIG7 expression, such as patient 1 and patient 4 in t(8;21) AMLs, tended to be more responsive to the ectopic expression of PIG7 (Figures 6a, c, e  and g ). It seems most likely that this difference between patients is correlated to the endogenous PIG7 expression. The role of PIG7 in primary leukemia cells requires validation in a prospective multicenter study with larger case numbers.
In conclusion, our findings implicate that within the process of differentiation and apoptosis of leukemia cells with AML1-ETO induced by PB, AMLlb is upregulated, which subsequently induces the expression of PIG7. Enforcing expression of PIG7 can induce differentiation and promote apoptosis in Kasumi-1, SKNO-1 cells and primary AMLs with t(8;21). Why PIG7 has this direct effect mainly on cells with AML1-ETO fusion gene, and whether other factors are involved in the effective regulation of PIG7 remain unclear and need further investigation.
